The UK and US have established a key commercial pact that will guarantee no import taxes on British medicine products going into the American market.
The Terms of the Accord
In exchange for the tariff guarantee, the UK has agreed to boost expenditure on pharmaceuticals through the National Health Service (NHS). This commitment ensures that tariffs on these vital exports will stay at nothing for a timeframe of three years.
This deal follows earlier threats to significantly raise duties on branded pharmaceutical products, with potential rates mentioned as high as one hundred percent.
"This agreement with the UK bolsters the worldwide climate for cutting-edge drugs and introduces much-needed balance to transatlantic drug exports," an announcement noted.
Trade Importance
Drugs are one of the UK's largest goods shipped to the United States, which is by far the biggest destination for large British pharmaceutical firms.
Statistics indicate that in the 12 months to the end of September, the UK sold drugs worth £11.1bn to the US. This amount represented 17.4% of total UK exports in that period.
"This agreement safeguards jobs, stimulates investment and sets the stage for the UK to establish itself as a international leader for biotech and pharma," a minister stated.
Specific NHS Changes
The pact involves several notable changes from the UK:
- Price Threshold Increase: The UK will lift the cost ceiling at which it deems new medicines to be too expensive by 25%.
- Higher Drug Budget: There is a aim to raise total NHS spending on drugs from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Payback Limit: The percentage pharmaceutical firms must return to the NHS to prevent overspending will be capped at fifteen percent. Previously, rebates exceeded 20%.
Recent Tensions
This agreement follows a long-running row between the drug companies and the ministers over spending levels and NHS adoption.
The disagreement were exacerbated by claims that US consumers were paying significantly more for the equivalent treatments than consumers in the Britain and the EU.
In recent months, several significant manufacturing plans in the UK have been halted or abandoned, while multi-billion-dollar funding commitments have been pledged toward projects in the United States.
One official publicly accepted that the NHS needed to spend more on treatments, noting that its budget allocation on drugs had declined as a proportion of its total funding over the previous ten-year period.
